Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

被引:189
作者
Boccadoro, Mario [1 ]
Morgan, Gareth [2 ]
Cavenagh, Jamie [3 ]
机构
[1] Univ Turin, Sect Hematol, Turin, Italy
[2] Royal Marsden Hosp, Surrey, England
[3] St Bartholomews Hosp, Dept Haematol, London, England
关键词
Multiple Myeloma; Bortezomib; Daclizumab; Endoplasmic Reticulum Stress Response; Multiple Myeloma Cell;
D O I
10.1186/1475-2867-5-18
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome that is indicated for single-agent use in the treatment of patients with multiple myeloma who have received at least 2 prior therapies and are progressing on their most recent therapy. Clinical investigations have been completed or are under way to evaluate the safety and efficacy of bortezomib alone or in combination with chemotherapy in multiple myeloma, both at relapse and presentation, as well as in other cancer types. The antiproliferative, proapoptotic, antiangiogenic, and antitumor activities of bortezomib result from proteasome inhibition and depend on the altered degradation of a host of regulatory proteins. Exposure to bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor kappa B-alpha, which prevents activation of nuclear factor.B-induced cell survival pathways. Bortezomib also promoted the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. In these preclinical in vivo studies, bortezomib treatment resulted in decreased tumor growth, angiogenesis, and metastasis, as well as increased survival and tumor apoptosis. In several in vitro and/or in vivo cancer models, bortezomib has also been shown to enhance the antitumor properties of several antineoplastic treatments. Importantly, bortezomib was generally well tolerated and did not appear to produce additive toxicities when combined with other therapies in the dosing regimens used in these preclinical in vivo investigations. These findings provide a rationale for further clinical trials using bortezomib alone or in combination regimens with chemotherapy, radiation therapy, immunotherapy, or novel agents in patients with hematologic malignancies or solid tumors.
引用
收藏
页数:9
相关论文
共 64 条
[1]  
Adams J, 1999, CANCER RES, V59, P2615
[2]   The development of proteasome inhibitors as anticancer drugs [J].
Adams, J .
CANCER CELL, 2004, 5 (05) :417-421
[3]  
Aghajanian C, 2002, CLIN CANCER RES, V8, P2505
[4]   Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma [J].
Amiri, KI ;
Horton, LW ;
LaFleur, BJ ;
Sosman, JA ;
Richmond, A .
CANCER RESEARCH, 2004, 64 (14) :4912-4918
[5]  
Bancroft CC, 2001, CLIN CANCER RES, V7, P435
[6]   Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome [J].
Bold, RJ ;
Virudachalam, S ;
McConkey, DJ .
JOURNAL OF SURGICAL RESEARCH, 2001, 100 (01) :11-17
[7]   Ubiquitin-mediated degradation of the proapoptotic active form of bid - A functional consequence on apoptosis induction [J].
Breitschopf, K ;
Zeiher, AM ;
Dimmeler, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (28) :21648-21652
[8]   New drugs for treatment of multiple myeloma [J].
Bruno, B ;
Rotta, M ;
Giaccone, L ;
Massaia, M ;
Bertola, A ;
Palumbo, A ;
Boccadoro, M .
LANCET ONCOLOGY, 2004, 5 (07) :430-442
[9]   Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells [J].
Chauhan, D ;
Li, GL ;
Podar, K ;
Hideshima, T ;
Mitsiades, C ;
Schlossman, R ;
Munshi, N ;
Richardson, P ;
Cotter, FE ;
Anderson, KC .
BLOOD, 2004, 104 (08) :2458-2466
[10]   Phase I study of bortezomib in refractory or relapsed acute leukemias [J].
Cortes, J ;
Thomas, D ;
Koller, C ;
Giles, F ;
Estey, E ;
Faderl, S ;
Garcia-Manero, G ;
McConkey, D ;
Patel, G ;
Guerciolini, R ;
Wright, J ;
Kantarjian, H .
CLINICAL CANCER RESEARCH, 2004, 10 (10) :3371-3376